J&J dumps a failed PhI­II an­tibi­ot­ic pro­gram picked up in Acte­lion buy­out

J&J is wash­ing its hands of the Phase III Clostrid­i­um dif­fi­cile-as­so­ci­at­ed di­ar­rhea pro­gram for the an­tibi­ot­ic cada­zol­id.

The phar­ma gi­ant ob­tained rights to the an­tibi­ot­ic in their $30 bil­lion buy­out of Acte­lion. But as the deal was be­ing com­plet­ed, cada­zol­id floun­dered — hit­ting the goal posts in one study but miss­ing in an­oth­er — af­ter re­cruit­ing 1,263 pa­tients to com­pare 250 mg of cada­zol­id twice dai­ly against 4 dai­ly dos­es of 125 mg van­comycin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER